What type of treatment may be deferred in cases of follicular lymphoma?

• A. Chemotherapy for aggressive subtypes
• B. Radiation for bulky nodal disease
• C. Immunotherapy for indolent disease
• D. Immediate chemotherapy for asymptomatic cases

Answer: (D)

In cases of follicular lymphoma, immediate chemotherapy may be deferred for asymptomatic patients. Follicular lymphoma typically follows an indolent course, meaning that it often grows slowly and may not require immediate intervention if a patient is asymptomatic. The rationale behind this approach is based on the understanding that many patients may live for a long time without treatment, and the urgency to initiate therapy decreases significantly in the absence of symptoms.

When patient symptoms are mild or non-existent, a watch-and-wait strategy is often implemented, allowing for the monitoring of the disease's progression. Initiating chemotherapy in asymptomatic cases can expose patients to the potential side effects and complications of treatment without a clear benefit, as the disease may not be actively harming them.

In contrast, treatments such as chemotherapy for aggressive subtypes or for symptomatic patients with more aggressive forms of lymphoma would necessitate prompt action due to the high risk of progression and morbidity. Radiation might also be used for bulky disease to alleviate symptoms or complications from large masses. Immunotherapy, while beneficial, may also be initiated based on specific clinical scenarios but is generally directed towards symptomatic patients or particular cases where more aggressive treatment is indicated, rather than being deferred in asymptomatic patients.